Hemab Therapeutics (NASDAQ:COAG) Major Shareholder Buys $989,149.89 in Stock

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG – Get Free Report) major shareholder Ra Capital Management, L.P. acquired 39,869 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was acquired at an average price of $24.81 per share, for a total transaction of $989,149.89. Following the completion of the purchase, the insider directly owned 6,365,783 shares of the company’s stock, valued at $157,935,076.23. This trade represents a 0.63% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

Get Hemab Therapeutics alerts:

• On Friday, May 8th, Ra Capital Management, L.P. acquired 1,483 shares of Hemab Therapeutics stock. The stock was acquired at an average price of $24.98 per share, for a total transaction of $37,045.34.
• On Thursday, May 7th, Ra Capital Management, L.P. acquired 9,906 shares of Hemab Therapeutics stock. The stock was acquired at an average price of $24.46 per share, for a total transaction of $242,300.76.
• On Wednesday, May 6th, Ra Capital Management, L.P. purchased 68,018 shares of Hemab Therapeutics stock. The shares were purchased at an average price of $24.60 per share, for a total transaction of $1,673,242.80.
• On Tuesday, May 5th, Ra Capital Management, L.P. purchased 97,411 shares of Hemab Therapeutics stock. The shares were purchased at an average price of $24.63 per share, for a total transaction of $2,399,232.93.
• On Monday, May 4th, Ra Capital Management, L.P. purchased 2,675,000 shares of Hemab Therapeutics stock. The shares were purchased at an average price of $18.00 per share, for a total transaction of $48,150,000.00.

Hemab Therapeutics Stock Performance

Shares of COAG opened at $28.56 on Thursday. Hemab Therapeutics Holdings, Inc. has a 12-month low of $23.00 and a 12-month high of $36.61.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th.

View Our Latest Analysis on COAG

Hemab Therapeutics Company Profile

(Get Free Report)

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.

Further Reading

• Five stocks we like better than Hemab Therapeutics
• D-Wave Earnings Looked Weak, But Investors May Be Missing This
• Nebius Upside Expands as AI Feedback Loop Intensifies
• Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
• Plug Power Flips The Switch On Profitability

Receive News & Ratings for Hemab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.